Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 5:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 68 matching trials from the live ClinicalTrials.gov search.
Conditions
Pancreatic Cancer
Interventions
CART-meso-19 T cells, Cyclophosphamide
Biological · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Francisco, California
Conditions
Leukemia, Myeloid, Acute, Leukemia, B-cell, Leukemia, T-Cell
Interventions
Treatment Arm A
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2044
U.S. locations
2
States / cities
Houston, Texas
Conditions
Generalized Myasthenia Gravis (gMG)
Interventions
CABA-201
Biological
Lead sponsor
Cabaletta Bio
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
17
States / cities
Orange, California • Sacramento, California • San Francisco, California + 12 more
Conditions
Relapsed/Refractory Acute Myeloid Leukemia
Interventions
AMG 553
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
3
States / cities
Duarte, California • Palo Alto, California • Houston, Texas
Conditions
Large-cell Lymphoma
Interventions
Rapcabtagene autoleucel (YTB323)
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Interventions
Asciminib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Leptomeninges, Breast Cancer, HER2-positive Breast Cancer
Interventions
Chimeric Antigen Receptor T-Cell Therapy
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Duarte, California
Conditions
Breast Cancer, Tumor, Breast, Breast Tumor, Malignant Neoplasm of Breast, Mammary Cancer, Mammary Neoplasm, Mammary Neoplasms, Human, Neoplasm, Breast
Interventions
HTR2 T Cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2044
U.S. locations
1
States / cities
Houston, Texas
Conditions
Central Nervous System Tumor, Pediatric, Glioma, Ependymoma, Medulloblastoma, Germ Cell Tumor, Atypical Teratoid/Rhabdoid Tumor, Primitive Neuroectodermal Tumor, Choroid Plexus Carcinoma, Pineoblastoma
Interventions
HER2-specific chimeric antigen receptor (CAR) T cell
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 26 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2039
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Multiple Myeloma
Interventions
Cilta-cel, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Stanford, California + 16 more
Conditions
Metastatic Breast Cancer
Interventions
huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells, huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D
Biological
Lead sponsor
Minerva Biotechnologies Corporation
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2035
U.S. locations
1
States / cities
Duarte, California
Conditions
MuSK Myasthenia Gravis
Interventions
MuSK-CAART
Biological
Lead sponsor
Cabaletta Bio
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Orange, California • Sacramento, California • Kansas City, Kansas + 2 more
Conditions
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Interventions
AUTO1
Biological
Lead sponsor
Autolus Limited
Industry
Eligibility
0 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 7 more
Conditions
Lymphoma, Myeloma, Leukemia
Interventions
Kappa CD28 T cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2035
U.S. locations
2
States / cities
Houston, Texas
Conditions
Hepatocellular Carcinoma
Interventions
GLYCAR T cells, Cytoxan, Fludarabine
Genetic · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Glioma
Interventions
CARv3-TEAM-E T cells
Drug
Lead sponsor
Marcela V. Maus, M.D.,Ph.D.
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma
Interventions
CD30.CAR-EBVST cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2040
U.S. locations
2
States / cities
Houston, Texas
Conditions
Multiple Myeloma
Interventions
Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib
Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
46
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 35 more
Conditions
Liver Cancer, Rhabdomyosarcoma, Malignant Rhabdoid Tumor, Liposarcoma, Wilms Tumor, Yolk Sac Tumor
Interventions
AGAR T cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 21 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2040
U.S. locations
1
States / cities
Houston, Texas
Conditions
Non-Hodgkin's Lymphoma, B-Cell ALL, B-Cell CLL
Interventions
CD19.CAR-CD28Z T Cells - dose escalation 2, CD19.CAR-CD28Z T Cells - dose escalation 1
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
2
States / cities
Houston, Texas
Conditions
Non-hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Interventions
CD19.CAR-multiVST for Group A, CD19.CAR-multiVST for Group B
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2040
U.S. locations
2
States / cities
Houston, Texas
Conditions
Liver Cell Carcinoma, Solid Tumor, Wilms Tumor, Malignant Rhabdoid Tumor, Yolk Sac Tumor, Rhabdomyosarcoma, Liposarcoma, Embryonal Sarcoma of the Liver
Interventions
CATCH T cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2040
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hematopoietic/Lymphoid Cancer, Acute Myeloid Leukemia
Interventions
Leukapheresis, Fludarabine, Cyclophosphamide, CD33-CAR-T Cell Infusion
Procedure · Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Philadelphia-Negative ALL, Philadelphia-Positive ALL, Relapsed ALL, Adult, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Acute Lymphoid Leukemia in Relapse
Interventions
19-28z/IL-18 CAR T cells
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
17 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more